通策医疗(600763) - 2023 Q3 - 季度财报

Financial Performance - Q3 2023 revenue reached RMB 822,177,057.03, a slight increase of 0.11% year-over-year[3] - Net profit attributable to shareholders was RMB 207,320,408.11, down 5.58% compared to the same period last year[3] - Basic earnings per share (EPS) stood at RMB 0.65, reflecting a decrease of 5.80% year-over-year[3] - Total revenue for the first three quarters of 2023 reached ¥2,184,842,620.45, an increase from ¥2,139,407,879.28 in the same period of 2022, representing a growth of approximately 2.1%[13] - Operating profit for Q3 2023 was ¥684,210,653.58, slightly up from ¥681,948,751.80 in Q3 2022, indicating a stable performance[15] - Net profit for Q3 2023 was ¥612,022,632.84, compared to ¥601,483,858.10 in Q3 2022, reflecting an increase of about 1.9%[15] - The net profit attributable to the parent company's shareholders for Q3 2023 is approximately ¥511.73 million, a slight decrease from ¥515.17 million in Q3 2022, representing a decline of about 0.86%[16] - The net profit for minority shareholders increased to approximately ¥100.29 million in Q3 2023, up from ¥86.31 million in Q3 2022, reflecting a growth of approximately 16.2%[16] - The total comprehensive income for Q3 2023 is approximately ¥608.92 million, compared to ¥579.23 million in Q3 2022, indicating an increase of about 5.14%[16] - The basic and diluted earnings per share for Q3 2023 are both ¥1.60, unchanged from Q3 2022[17] Assets and Liabilities - Total assets increased to RMB 5,804,980,328.20, representing a growth of 12.62% from the end of the previous year[4] - Total assets as of Q3 2023 amounted to ¥5,804,980,328.20, up from ¥5,154,452,885.95 in Q3 2022, marking a growth of approximately 12.6%[13] - Non-current assets totaled ¥4,668,713,116.11 in Q3 2023, compared to ¥4,042,564,793.73 in Q3 2022, an increase of around 15.5%[12] - Current liabilities decreased to ¥437,343,812.97 in Q3 2023 from ¥477,456,007.35 in Q3 2022, a reduction of about 8.5%[12] - The total liabilities as of Q3 2023 were ¥1,639,908,795.75, compared to ¥1,536,223,702.61 in Q3 2022, reflecting an increase of about 6.7%[13] - The company reported a decrease in accounts payable to ¥105,943,696.78 in Q3 2023 from ¥140,519,901.44 in Q3 2022, a decline of approximately 24.6%[12] Shareholder Information - Total number of common shareholders at the end of the reporting period is 84,364, with the largest shareholder, Hangzhou Baoqun Industrial Group Co., Ltd., holding 108,232,000 shares, representing 33.75%[8] - The company has not reported any significant changes in the number of shares held by the top ten shareholders, maintaining stability in ownership structure[9] - The company has no pledged, marked, or frozen shares among the top ten shareholders, indicating a stable financial position[8] Cash Flow - Cash flow from operating activities for the year-to-date increased by 22.27% to RMB 625,699,942.97[3] - The net cash flow from operating activities for the first three quarters of 2023 is approximately ¥625.70 million, an increase from ¥511.76 million in the same period of 2022, representing a growth of about 22.2%[18] - Cash inflow from operating activities totaled approximately ¥2.19 billion in the first three quarters of 2023, compared to ¥2.13 billion in the same period of 2022, marking an increase of about 3%[18] - The net cash flow from investing activities for Q3 2023 is approximately -¥638.49 million, worsening from -¥384.52 million in Q3 2022[20] - The net cash flow from financing activities for Q3 2023 is approximately ¥63.74 million, a significant improvement from -¥277.10 million in Q3 2022[20] - The cash and cash equivalents at the end of Q3 2023 amount to approximately ¥680.50 million, a decrease from ¥693.18 million at the end of Q3 2022[20] - The company reported a total cash inflow from financing activities of approximately ¥283.84 million in Q3 2023, compared to ¥22.07 million in Q3 2022, indicating a substantial increase[20] Investments and Projects - Long-term equity investments surged by 207.63% primarily due to the acquisition of Ren Technology shares[7] - The company reported a 61.42% increase in construction in progress, attributed to renovations for new hospital projects[7] - Research and development expenses for Q3 2023 were ¥43,854,031.34, slightly higher than ¥43,738,599.33 in Q3 2022, indicating continued investment in innovation[15] Other Information - The report does not indicate any new product launches or technological advancements during the quarter, focusing instead on financial performance metrics[10] - There are no significant mergers or acquisitions reported in the current quarter, with the company concentrating on internal growth strategies[10]